296 related articles for article (PubMed ID: 31589086)
1. Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured population.
Wu B; Li SS; Song J; Pericone CD; Behl AS; Dawson NA
J Med Econ; 2020 Jan; 23(1):54-63. PubMed ID: 31589086
[No Abstract] [Full Text] [Related]
2. Healthcare Costs in Men with Metastatic Castration-Resistant Prostate Cancer: An Analysis of US Medicare Fee-For-Service Claims.
Freedland SJ; Davis MR; Epstein AJ; Arondekar B; Ivanova JI
Adv Ther; 2023 Oct; 40(10):4480-4492. PubMed ID: 37531024
[TBL] [Abstract][Full Text] [Related]
3. Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiation.
Kaye DR; Khilfeh I; Muser E; Morrison L; Kinkead F; Urosevic A; Lefebvre P; Pilon D; George DJ
J Med Econ; 2024; 27(1):201-214. PubMed ID: 38204397
[TBL] [Abstract][Full Text] [Related]
4. Treatment patterns and healthcare resource utilization in patients with metastatic hormone-sensitive prostate cancer and nonmetastatic castration-resistant prostate cancer in China: a real-world observational study.
Wang Y; Liu C; Liu C; Lu Y; Ban L; Niu Y
J Med Econ; 2024; 27(1):361-369. PubMed ID: 38375556
[TBL] [Abstract][Full Text] [Related]
5. Predictors of survival, healthcare resource utilization, and healthcare costs in veterans with non-metastatic castration-resistant prostate cancer.
Freedland SJ; Pilon D; Bhak RH; Lefebvre P; Li S; Young-Xu Y
Urol Oncol; 2020 Dec; 38(12):930.e13-930.e21. PubMed ID: 32739230
[TBL] [Abstract][Full Text] [Related]
6. Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
Schultz NM; O'Day K; Sugarman R; Ramaswamy K
J Manag Care Spec Pharm; 2020 Apr; 26(4):538-549. PubMed ID: 32020841
[TBL] [Abstract][Full Text] [Related]
7. A Retrospective Claims Analysis of Advanced Prostate Cancer Costs and Resource Use.
Appukkuttan S; Tangirala K; Babajanyan S; Wen L; Simmons S; Shore N
Pharmacoecon Open; 2020 Sep; 4(3):439-447. PubMed ID: 31641995
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations.
Armstrong A; Bui C; Fitch K; Sawhney TG; Brown B; Flanders S; Balk M; Deangelis J; Chambers J
Curr Med Res Opin; 2017 Jun; 33(6):1133-1139. PubMed ID: 28318331
[TBL] [Abstract][Full Text] [Related]
9. Values of alkaline phosphatase at the diagnosis of castration resistance and response to primary androgen deprivation therapy as predictors of subsequent metastasis in non-metastatic castration-resistant prostate cancer.
Mori K; Kimura T; Fukuokaya W; Iwatani K; Sakanaka K; Kurokawa G; Yanagisawa T; Sasaki H; Miki J; Shimomura T; Miki K; Hatano T; Endo K; Egawa S
Int J Clin Oncol; 2020 Mar; 25(3):479-485. PubMed ID: 31512007
[TBL] [Abstract][Full Text] [Related]
10. Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer.
Appukkuttan S; Farej R; Miles L; Purser M; Wen L
J Manag Care Spec Pharm; 2021 Feb; 27(2):166-174. PubMed ID: 33141615
[No Abstract] [Full Text] [Related]
11. The cost impact of disease progression to metastatic castration-sensitive prostate cancer.
Trinh QD; Chaves LP; Feng Q; Zhu J; Sandin R; Abbott T
J Manag Care Spec Pharm; 2022 May; 28(5):544-554. PubMed ID: 35471070
[No Abstract] [Full Text] [Related]
12. Health Care Resource Utilization and Costs Associated with Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis.
Schultz NM; Penson DF; Wilson SD; Song Y; Yang H; Ramaswamy K; Lowentritt B
J Manag Care Spec Pharm; 2019 Aug; 25(8):889-897. PubMed ID: 31172866
[TBL] [Abstract][Full Text] [Related]
13. Patients' preferences for delaying metastatic castration-resistant prostate cancer: Combining health state and treatment valuation.
Rentz AM; Mansukhani SG; Liu J; Lloyd AJ; Heidenreich S; Matza LS; Dawson NA; Shore N; Freedland SJ
Urol Oncol; 2021 Jun; 39(6):367.e7-367.e17. PubMed ID: 33736976
[TBL] [Abstract][Full Text] [Related]
14. Disease-related and all-cause health care costs of elderly patients with gout.
Wu EQ; Patel PA; Yu AP; Mody RR; Cahill KE; Tang J; Krishnan E
J Manag Care Pharm; 2008 Mar; 14(2):164-75. PubMed ID: 18331118
[TBL] [Abstract][Full Text] [Related]
15. Treatment patterns, comorbidities, healthcare resource use, and associated costs by line of chemotherapy and level of comorbidity in patients with newly-diagnosed Merkel cell carcinoma in the United States.
Kearney M; Thokagevistk K; Boutmy E; Bharmal M
J Med Econ; 2018 Dec; 21(12):1159-1171. PubMed ID: 30149739
[TBL] [Abstract][Full Text] [Related]
16. Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States.
Ryan CJ; Ke X; Lafeuille MH; Romdhani H; Kinkead F; Lefebvre P; Petrilla A; Pulungan Z; Kim S; D'Andrea DM; Francis P; Freedland SJ
J Urol; 2021 Dec; 206(6):1420-1429. PubMed ID: 34293915
[TBL] [Abstract][Full Text] [Related]
17. Survival and Economic Impact of Rapid Prostate-Specific Antigen Doubling Time in Patients With Nonmetastatic Castration-Resistant Prostate Cancer.
Freedland SJ; Ramaswamy K; Huang A; Sandin R; Mardekian J; Schultz NM; Janjan N; George DJ
Clin Genitourin Cancer; 2023 Aug; 21(4):419-429. PubMed ID: 36842915
[TBL] [Abstract][Full Text] [Related]
18. Healthcare resource use in advanced prostate cancer patients treated with docetaxel.
Mehra M; Wu Y; Dhawan R
J Med Econ; 2012; 15(5):836-43. PubMed ID: 22463616
[TBL] [Abstract][Full Text] [Related]
19. Time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer, and its health economic impact: registry-based study in Sweden.
Svensson J; Lissbrant IF; Gauffin O; Hjälm-Eriksson M; Kilany S; Fagerlund K; Stattin P
Scand J Urol; 2021 Feb; 55(1):1-8. PubMed ID: 33300403
[TBL] [Abstract][Full Text] [Related]
20. The Health Economics of Metastatic Hormone-Sensitive and Non-Metastatic Castration-Resistant Prostate Cancer-A Systematic Literature Review with Application to the Canadian Context.
Yanev I; Gatete J; Aprikian AG; Guertin JR; Dragomir A
Curr Oncol; 2022 May; 29(5):3393-3424. PubMed ID: 35621665
[No Abstract] [Full Text] [Related]
[Next] [New Search]